Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia
GSK announced that the U.S. FDA has granted Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag).
-
GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma
GSK announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) met its primary endpoint of PFS
-
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes
GlaxoSmithKline plc today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion albiglutide
-
ViiV Healthcare’s new HIV medicine TivicayTM (dolutegravir) is approved in Europe
ViiV Healthcare today announced that the European Commission has approved TivicayTM (dolutegravir).
-
Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)
Prosensa Holding N.V. (NASDAQ: RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to drisapersen.
-
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
GSK announced today that the U.S. FDA has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib).
-
GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)
GSK announced today that the FDA has approved Mekinist® (trametinib) for use with Tafinlar® (dabrafenib) for the treatment melanoma
-
GSK adds detailed clinical trial data to multi-sponsor request system as part of continued commitment to data transparency
GSK added its anonymised patient-level data from the online request system it launched in May 2013 to a new multi-sponsor request system.
-
GSK completes divestment of thrombosis brands and related manufacturing site to Aspen
GlaxoSmithKline (GSK) today completed the previously announced divestment of its thrombosis brands, ArixtraTM and FraxiparineTM.
-
GSK completes divestment of Lucozade and Ribena to Suntory
GSK today completed the previously announced divestment of its nutritional drinks brands Lucozade and Ribena.
-
GSK Cervarix® two-dose schedule receives European marketing authorisation
GSK announced today that the European Commission has granted marketing authorisation for its cervical cancer vaccine Cervarix.
-
GSK and MMV announce FDA Breakthrough Therapy designation for tafenoquine for Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) announced today that the FDA has granted Breakthrough Therapy designation for tafenoquine.
-
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
-
GSK announces 1 million innovation prize for bioelectronics research
GSK is announcing today a $1 million dollar prize for innovation in the emerging area of bioelectronics research.
-
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc and Theravance, Inc. today announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA.
-
GSK announces changes to its global sales and marketing practices to further ensure patient interests come first
GSK today set out plans to evolve the way it sells and markets its products to healthcare professionals.
-
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab Receive Priority Review from FDA for Arzerra® (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukaemia (CLL)
-
GSK initiates voluntary open offer to increase stake in its pharmaceuticals subsidiary in India
GSK today announced a Voluntary Open Offer to increase its stake in its publicly-listed pharmaceuticals subsidiary in India.
-
GSK announces £200 million investment in UK advanced manufacturing and science
GSK announced a series of investments totalling approx £200million for new medicines and to create a centre for pharmaceutical manufacturing
-
Update regarding 2010 Nature Medicine study
A GSK research paper published in 2010 that was found earlier this year to contain incorrect data has now been retracted by Nature Medicine.
